EGFR and malignant glioma: In a clinical study of EGFR tyrosine kinase inhibitor (erlotinib) on malignant gliomas patients, AKT activation status was found to determine the response of the tissue to the inhibitor (Haas-Kogan et al. 2005), suggesting that p-AKT had mediated EGFR signaling in the patients.